THOUSAND OAKS, Calif. (March 23, 2018) - 世界杯比赛时间 Amgen (NASDAQ:AMGN) today announced that the Committee for 2026世界杯直播赛程 世界杯直播频道 Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion
世界杯比赛时间 to include a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce
世界杯直播频道 世界杯直播频道 cardiovascular risk by 世界杯直播频道 lowering LDL-C levels. The recommended label recognizes the positive findings from the Repatha cardiovascular outcomes study (FOURIER) and includes data on the additional reduction
世界杯比赛时间 世界杯比赛时间 and prevention of heart attacks, strokes and coronary revascularizations 世界杯比赛时间 on top of maximally tolerated statin therapy.
The Repatha cardiovascular outcomes study showed reductions in 世界杯比赛时间 the risk of heart attack by 27 percent, 世界杯直播频道 the risk of stroke by 21 percent and the risk of coronary revascularization procedures by 22 percent in
世界杯直播频道 世界杯直播频道 patients treated with Repatha and statin therapy 世界杯比赛时间 compared to patients treated with placebo and statin therapy over a mean duration of 26 months.
“We welcome the CHMP’s positive opinion to incorporate a new indication for adults with cardiovascular disease into the European label, recognizing the impact of Repatha to prevent life-changing events such
世界杯比赛时间 as heart attacks and strokes,” said Sean E. Harper, M.D., executive vice president of Research 世界杯比赛时间 世界杯直播频道 and Development at Amgen. “With the FOURIER outcomes data now included in the U.S. label 世界杯直播频道 and an anticipated
世界杯比赛时间 世界杯直播频道 label update in Europe in the coming months, we will continue to work with payers globally 世界杯比赛时间 to ensure access to medication for higher-risk patients. Furthermore, we value and support the efforts by many stakeholders,
世界杯直播频道 including clinicians, advocates and payers, as we all work to reduce barriers to access and increase affordability for patients who need PCSK9 treatment.”
The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). If approved, the centralized
European marketing authorization for 2026世界杯直播赛程 Repatha will be updated 世界杯直播频道 to 2026世界杯直播赛程 include the new indication. Norway, Iceland and Liechtenstein, as members of the European Economic Area (EEA), will take corresponding decisions
2026世界杯直播赛程 on the basis of the EC’s decision.
On Dec. 1, 2017, the U.S. Food 世界杯比赛时间 and Drug Administration (FDA) approved a new indication for Repatha as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with
世界杯比赛时间 established cardiovascular disease following a priority review of Amgen’s supplemental Biologics License Application.
Repatha Cardiovascular Outcomes (FOURIER) Study: Key Outcomes
The 27,564-patient Repatha cardiovascular outcomes study (FOURIER) demonstrated that adding Repatha to optimized statin therapy resulted 世界杯比赛时间 2026世界杯直播赛程 in a statistically 世界杯直播频道 significant 20 percent (p<0.001) reduction
世界杯比赛时间 in major adverse cardiovascular events 世界杯比赛时间 (MACE) represented in the key secondary composite endpoint of time to first heart attack, stroke or cardiovascular death. The study found a statistically significant
世界杯直播频道 世界杯比赛时间 15 2026世界杯直播赛程 percent reduction (p<0.001) in the risk of the primary composite endpoint, which included hospitalization for unstable angina, coronary revascularization, heart attack, stroke or cardiovascular
世界杯比赛时间 death.
The magnitude of 2026世界杯直播赛程 risk reduction in both the primary and key secondary composite endpoints grew over time, 世界杯比赛时间 with the robust benefit starting as early 世界杯比赛时间 as six months and accruing through the 世界杯比赛时间 median 2.2 years of
世界杯直播频道 世界杯直播频道 世界杯直播频道 the study.
Patients on Repatha experienced a reduction in the risk of heart attack (27 percent, nominal p<0.001), stroke (21 percent, nominal p=0.01) and coronary revascularization (22 percent, nominal
世界杯直播频道 世界杯比赛时间 p<0.001).1 Consistent with recent trials of more intensive LDL-C lowering, there was no observed effect on cardiovascular mortality. Similarly, there was no observed effect on hospitalization
世界杯比赛时间 2026世界杯直播赛程 for unstable angina.2-6
The safety profile of Repatha in the outcomes trial 2026世界杯直播赛程 was generally consistent with the safety profile for the 12- and 52-week controlled trials involving patients with primary hyperlipidemia, including heterozygous
familial 世界杯比赛时间 hypercholesterolemia (HeFH).
Repatha Cardiovascular Outcomes (FOURIER) Study Design
FOURIER (Further Cardiovascular OUTcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a multinational Phase 3 randomized, double-blind, placebo-controlled trial, is designed to evaluate whether
2026世界杯直播赛程 世界杯比赛时间 世界杯比赛时间 世界杯直播频道 2026世界杯直播赛程 treatment with Repatha in combination 世界杯直播频道 with high- or moderate-intensity statin therapy compared to placebo plus statin therapy 世界杯比赛时间 2026世界杯直播赛程 reduces cardiovascular events. The hard MACE composite endpoint is the time to
世界杯直播频道 cardiovascular death, myocardial infarction 世界杯比赛时间 or stroke (key secondary endpoint). The extended MACE composite endpoint is the 世界杯直播频道 time to cardiovascular death, myocardial infarction, stroke, or hospitalization
2026世界杯直播赛程 世界杯比赛时间 2026世界杯直播赛程 2026世界杯直播赛程 世界杯直播频道 for unstable angina or coronary revascularization (primary endpoint).
Eligible patients with high cholesterol (LDL-C ≥70 mg/dL 2026世界杯直播赛程 or non-high-density 世界杯直播频道 lipoprotein 世界杯直播频道 cholesterol [non-HDL-C] ≥100 mg/dL) and established cardiovascular disease at more than 1,300 study locations 2026世界杯直播赛程 around the
世界杯比赛时间 world were randomized to receive Repatha subcutaneous 140 mg every two 世界杯比赛时间 weeks 2026世界杯直播赛程 or 420 mg monthly plus high- or moderate-intensity effective statin dose; or placebo subcutaneous every two weeks or monthly plus
世界杯直播频道 世界杯直播频道 high- to moderate-intensity statin dose. Statin therapy was defined in the protocol as at least atorvastatin 20 mg or equivalent daily with 世界杯直播频道 a recommendation for at 世界杯直播频道 least atorvastatin 40 mg or equivalent
世界杯直播频道 世界杯直播频道 daily where approved. The study was event driven and continued until at least 1,630 patients experienced a key secondary endpoint.
About Repatha® (evolocumab)
Repatha® 世界杯比赛时间 (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds 世界杯直播频道 to PCSK9 and inhibits circulating PCSK9 2026世界杯直播赛程 from binding to
2026世界杯直播赛程 the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha
世界杯直播频道 increases the number of LDLRs available to clear 世界杯直播频道 LDL from the blood, thereby lowering LDL-C levels.7
Repatha is approved in more than 60 countries, including the U.S., Japan, Canada, and in all 28 countries that are members of the European Union. Applications 2026世界杯直播赛程 世界杯比赛时间 in other countries are pending.
Important EU Product Information
In Europe Repatha is approved for use in:
Hypercholesterolemia and mixed dyslipidemia
Repatha is indicated in adults 世界杯直播频道 世界杯比赛时间 with primary hypercholesterolemia (heterozygous familial and non-familial) 2026世界杯直播赛程 or mixed dyslipidemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a 世界杯直播频道 statin or,
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, 2026世界杯直播赛程 or for whom a statin is contraindicated.
Homozygous familial hypercholesterolemia
Repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolemia in combination with other 世界杯比赛时间 lipid-lowering therapies.
Posology
Primary hypercholesterolaemia and mixed dyslipidaemia in adults
The 世界杯比赛时间 recommended dose of Repatha is either 140 mg every two weeks or 420 mg once monthly; both doses are clinically equivalent.
Homozygous familial hypercholesterolaemia in adults and adolescents aged 12 years and over
The initial recommended dose 2026世界杯直播赛程 is 420 mg once monthly. After 12 weeks of treatment, dose frequency can be up-titrated
世界杯比赛时间 世界杯直播频道 2026世界杯直播赛程 世界杯直播频道 世界杯比赛时间 to 420 mg once every 2 weeks if a clinically meaningful response is not achieved. Patients on apheresis 世界杯直播频道 may initiate treatment with 420 mg every two weeks to 2026世界杯直播赛程 世界杯比赛时间 correspond with their apheresis 世界杯比赛时间 schedule.
Important Safety Information
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report
2026世界杯直播赛程 世界杯比赛时间 any suspected adverse reactions.
Contraindications: Hypersensitivity to the active 世界杯直播频道 substance or to any of the excipients.
Special Warnings and Precautions: Renal impairment: Patients with severe renal impairment (defined as eGFR < 30 mL/min/1.73 m2) have not been studied. Repatha should be used 世界杯比赛时间 with caution in
世界杯比赛时间 patients with severe renal impairment. Hepatic impairment: In patients with moderate hepatic impairment, a reduction in total evolocumab exposure was observed that may lead to a reduced effect on
2026世界杯直播赛程 世界杯直播频道 世界杯比赛时间 LDLC reduction. Therefore, close monitoring may be warranted in these patients. Patients with severe hepatic impairment (Child-Pugh C) have not been studied. Repatha should be used with caution in patients
世界杯比赛时间 with severe hepatic impairment. Dry natural rubber: The needle cover of the glass pre-filled syringe and of the pre-filled pen is made from dry natural rubber (a derivative of latex), which may 世界杯比赛时间 2026世界杯直播赛程 cause
2026世界杯直播赛程 allergic reactions. Sodium content: Repatha contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially 'sodium-free'.
Interactions: No formal drug-drug interaction studies have been conducted for Repatha. No studies on pharmacokinetic and pharmacodynamics interaction between Repatha and lipid-lowering drugs other than
2026世界杯直播赛程 世界杯直播频道 世界杯比赛时间 statins and ezetimibe have been conducted.
Fertility, Pregnancy and Lactation: There are no or limited amount of data from the use of Repatha in pregnant women. Repatha should not be used during pregnancy unless the clinical condition of the woman
世界杯直播频道 世界杯直播频道 requires treatment with evolocumab. It is unknown whether evolocumab is excreted in human milk. A risk to breastfed newborns/infants cannot be excluded. No data on the effect of 世界杯比赛时间 evolocumab on human fertility
世界杯比赛时间 世界杯比赛时间 世界杯直播频道 are available.
Undesirable Effects: The following common (> 世界杯直播频道 1/100 to < 1/10) adverse reactions have been reported in pivotal, controlled clinical studies: influenza, nasopharyngitis, upper respiratory tract infection,
世界杯直播频道 rash, nausea, back pain, arthralgia, injection site reactions. Please consult the SmPC for a 世界杯直播频道 full description of undesirable effects.
Pharmaceutical Precautions: Store in a refrigerator (2 degrees C – 8 degrees C). Do not freeze. Keep the pre-filled syringe or the pre-filled pen in the original carton in order to protect from light.
世界杯直播频道 世界杯比赛时间 If removed from the refrigerator, Repatha may be stored at room temperature (up to 25 degrees C) in 2026世界杯直播赛程 the original carton and must be used within 1 month.
Important U.S. Product Information
Repatha is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody indicated:
- to reduce the risk 世界杯直播频道 of 世界杯比赛时间 myocardial infarction, stroke, and coronary revascularization 世界杯直播频道 in adults with established cardiovascular 2026世界杯直播赛程 disease.
- as an adjunct to diet, alone or in combination with other lipid-lowering 世界杯比赛时间 therapies (e.g., statins, 世界杯直播频道 ezetimibe), for treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia
2026世界杯直播赛程 [HeFH]) to reduce low-density lipoprotein cholesterol (LDL-C).
- as an adjunct to diet and other LDL lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with homozygous familial hypercholesterolemia (HoFH ) who require additional lowering of LDL C.
The safety and effectiveness of Repatha have not been established in pediatric patients with HoFH who are younger than 13 years old or in pediatric patients with primary hyperlipidemia or HeFH.
Important 世界杯直播频道 世界杯比赛时间 U.S. Safety Information
Contraindication: Repatha is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha.
Allergic reactions: Hypersensitivity reactions (e.g. rash, urticaria) have been reported 世界杯比赛时间 in patients treated with Repatha, including some that 世界杯比赛时间 led to discontinuation of therapy. If signs or symptoms of
世界杯直播频道 世界杯比赛时间 serious allergic reactions occur, discontinue treatment with Repatha, treat according to the standard of care, and monitor until signs and symptoms resolve.
Adverse reactions: The most common adverse reactions (>5 percent of Repatha-treated patients and occurring more frequently than placebo) in controlled trials involving patients with primary hyperlipidemia,
世界杯直播频道 including HeFH, were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.
In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2 percent of Repatha-treated patients and 1 percent of placebo-treated patients. The most common adverse reaction that led to Repatha
世界杯直播频道 世界杯比赛时间 世界杯直播频道 treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3 percent versus 0 percent for Repatha and placebo, respectively).
Adverse reactions from a pool of the 52-week trial and seven 12-week trials: Local injection site 世界杯直播频道 reactions occurred in 3.2 percent and 3.0 percent of Repatha-treated and placebo-treated patients, respectively.
世界杯比赛时间 世界杯比赛时间 2026世界杯直播赛程 The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in Repatha-treated patients and placebo-treated
世界杯直播频道 patients were 0.1 percent and 0 percent, respectively.
Allergic reactions occurred in 5.1 percent and 4.7 percent of Repatha-treated and placebo-treated patients, respectively. The most common 世界杯直播频道 allergic reactions were rash (1.0 percent versus 0.5 percent for Repatha
世界杯比赛时间 世界杯比赛时间 世界杯直播频道 世界杯比赛时间 and placebo, respectively), eczema (0.4 percent versus 0.2 percent), erythema (0.4 percent versus 0.2 世界杯直播频道 percent), and urticaria (0.4 percent versus 0.1 percent).
The safety profile of Repatha in the cardiovascular outcomes 世界杯直播频道 trial was generally consistent with the safety profile in the 12- and 52-week controlled trials involving patients with 世界杯直播频道 primary hyperlipidemia, including
世界杯直播频道 世界杯比赛时间 世界杯直播频道 世界杯直播频道 世界杯比赛时间 HeFH. Serious adverse events occurred in 24.8 percent and 24.7 percent of Repatha-treated and 世界杯比赛时间 placebo-treated patients, respectively. Adverse events led to discontinuation of study treatment in 4.4 percent
世界杯比赛时间 世界杯直播频道 of patients assigned to Repatha and 4.2 percent assigned to placebo. Common adverse reactions (>5 percent of patients treated with Repatha and occurring more frequently than placebo) included diabetes
世界杯直播频道 世界杯比赛时间 2026世界杯直播赛程 mellitus (8.8 percent Repatha, 8.2 percent placebo), nasopharyngitis (7.8 percent Repatha, 7.4 percent placebo) and upper respiratory tract infection (5.1 percent Repatha, 4.8 percent placebo). Among the
世界杯直播频道 世界杯直播频道 16,676 patients without 世界杯直播频道 diabetes 世界杯比赛时间 mellitus at baseline, the incidence 世界杯直播频道 of new-onset diabetes mellitus during the trial was 8.1 percent in patients assigned to Repatha compared with 7.7 percent in those assigned
2026世界杯直播赛程 世界杯比赛时间 to placebo.
Homozygous Familial Hypercholesterolemia (HoFH): In 49 patients with homozygous familial 世界杯直播频道 hypercholesterolemia studied in a 12-week, double-blind, randomized, 2026世界杯直播赛程 placebo-controlled trial, 33 patients received
世界杯比赛时间 世界杯直播频道 世界杯比赛时间 420 mg of Repatha subcutaneously once monthly. The adverse reactions that occurred 世界杯比赛时间 in at least 2 (6.1 percent) Repatha-treated patients and 世界杯比赛时间 more frequently than in placebo-treated patients, included upper
2026世界杯直播赛程 世界杯比赛时间 respiratory tract infection (9.1 percent versus 6.3 percent),
influenza (9.1 percent versus 0 percent), gastroenteritis (6.1 percent versus 0 percent), and nasopharyngitis (6.1 percent versus 0 percent).
Immunogenicity: Repatha is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with Repatha.
Please contact Amgen Medinfo at 800-77-AMGEN (800-772-6436) or 世界杯直播频道 844-REPATHA (844-737-2842) regarding Repatha® availability or find more information, including full Prescribing Information, at www.amgen.com and www.Repatha.com.
About Amgen in the Cardiovascular Therapeutic Area
Building on more than three decades of experience in developing biotechnology medicines for patients with serious illnesses, Amgen is 世界杯比赛时间 dedicated to
addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease, the leading cause of morbidity and mortality worldwide.8 Amgen's 世界杯直播频道 research into cardiovascular
世界杯直播频道 世界杯比赛时间 disease, and potential treatment options, is part of a growing competency at Amgen that utilizes human genetics to identify and validate certain drug targets. Through its own research and development efforts,
世界杯直播频道 2026世界杯直播赛程 as well as partnerships, Amgen is building a robust 世界杯比赛时间 2026世界杯直播赛程 cardiovascular portfolio consisting of several approved and investigational molecules in an effort to address a number of today's important unmet patient
needs, 世界杯直播频道 such as high cholesterol and heart failure.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the 世界杯直播频道 fundamentals of human 世界杯直播频道 biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980,
世界杯比赛时间 世界杯直播频道 世界杯比赛时间 Amgen has grown to be one of 世界杯比赛时间 the world's leading independent biotechnology companies, has reached 世界杯直播频道 millions of patients around the world and is developing 2026世界杯直播赛程 a pipeline of 2026世界杯直播赛程 medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations 2026世界杯直播赛程 and beliefs of Amgen. All statements, other than statements of historical
世界杯比赛时间 世界杯直播频道 世界杯直播频道 fact, are statements that 世界杯直播频道 could be deemed forward-looking statements, including estimates of 世界杯比赛时间 revenues, operating margins, capital expenditures, cash, other financial 世界杯比赛时间 metrics, expected legal, arbitration,
世界杯比赛时间 世界杯直播频道 political, regulatory or clinical results or practices, customer and prescriber patterns or practices, 世界杯比赛时间 reimbursement activities and outcomes and 2026世界杯直播赛程 other such estimates and 世界杯直播频道 results. Forward-looking statements
世界杯直播频道 世界杯比赛时间 involve significant risks and uncertainties, including those discussed below and more 世界杯直播频道 fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual 世界杯比赛时间 report
世界杯比赛时间 on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not
2026世界杯直播赛程 世界杯比赛时间 undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing
products cannot be guaranteed and movement from concept to 世界杯比赛时间 product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing
product will be successful and become a 世界杯直播频道 commercial product. Further, preclinical results do not guarantee safe and effective performance of 世界杯直播频道 product candidates in humans. The complexity of the human body
2026世界杯直播赛程 cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory
世界杯比赛时间 世界杯比赛时间 approval for product marketing has in the past 世界杯直播频道 varied and we expect similar variability in the future. Even when 世界杯比赛时间 clinical trials are successful, regulatory authorities may question the sufficiency for approval
世界杯比赛时间 世界杯比赛时间 世界杯直播频道 of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships
may be subject to disputes between the 世界杯比赛时间 parties or may prove to be not as effective or as safe as we may have believed at the 世界杯直播频道 time of entering into such 世界杯直播频道 relationship. Also, we or 2026世界杯直播赛程 others could identify safety,
世界杯直播频道 世界杯比赛时间 side effects or manufacturing problems with our 世界杯比赛时间 products, including our devices, after they are on the market.
Our results may be affected by 世界杯直播频道 our ability to successfully market both new and existing 世界杯直播频道 products domestically and internationally, clinical and regulatory developments involving current and future products,
世界杯直播频道 2026世界杯直播赛程 sales growth of 世界杯比赛时间 recently launched products, competition 2026世界杯直播赛程 from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales
of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers
世界杯直播频道 and may be affected by regulatory, clinical and guideline developments and domestic and 世界杯比赛时间 世界杯直播频道 international trends toward managed care and 世界杯比赛时间 healthcare cost containment. Furthermore, our research, testing, pricing,
世界杯直播频道 世界杯直播频道 2026世界杯直播赛程 marketing 世界杯比赛时间 and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product
2026世界杯直播赛程 世界杯直播频道 liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate
世界杯直播频道 世界杯比赛时间 世界杯比赛时间 世界杯比赛时间 世界杯比赛时间 integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered
世界杯直播频道 世界杯比赛时间 世界杯直播频道 世界杯直播频道 by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial
世界杯直播频道 2026世界杯直播赛程 世界杯直播频道 世界杯比赛时间 amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, 世界杯比赛时间 and also depend on third parties for a portion of our manufacturing activities, and limits on supply may
世界杯比赛时间 2026世界杯直播赛程 世界杯直播频道 constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with 世界杯比赛时间 respect to many of our marketed products as well as for the discovery
世界杯比赛时间 世界杯直播频道 世界杯比赛时间 and development of new products. Further, 世界杯比赛时间 some 世界杯比赛时间 世界杯直播频道 raw materials, medical 世界杯直播频道 世界杯比赛时间 devices and component parts for our 2026世界杯直播赛程 products are 世界杯直播频道 supplied by sole third-party suppliers. Certain of 世界杯比赛时间 our 世界杯直播频道 distributors, 世界杯直播频道 customers and payers
世界杯直播频道 2026世界杯直播赛程 have substantial purchasing leverage in their dealings with us. The 世界杯比赛时间 discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a
世界杯直播频道 世界杯比赛时间 世界杯直播频道 material adverse effect on sales of the affected products and on our 世界杯比赛时间 business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we
世界杯直播频道 have acquired may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our 2026世界杯直播赛程 stock price
世界杯直播频道 is 世界杯直播频道 volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our 世界杯直播频道 Board of Directors to declare a dividend or our ability to pay a 2026世界杯直播赛程 dividend or repurchase
2026世界杯直播赛程 2026世界杯直播赛程 世界杯比赛时间 世界杯比赛时间 our common stock. We may not be able to access the capital 世界杯直播频道 and credit markets on terms that are favorable to us, or at all.
CONTACT: Amgen, Thousand 世界杯直播频道 世界杯比赛时间 Oaks
Kristen Davis, 805-447-3008 (Media)
Kristen Neese, 805-313-8267 (Media) 世界杯直播频道
Arvind 世界杯直播频道 Sood, 805-447-1060 (Investors)
REFERENCES
- Sabatine MS, Giugliano RP, Keech AC, et 世界杯比赛时间 al, for the FOURIER Steering Committee and Investigators. N Engl J Med. Evolocumab 世界杯比赛时间 and Clinical Outcomes in 2026世界杯直播赛程 Patients 2026世界杯直播赛程 with Cardiovascular Disease. 2017;376:1713-22.
世界杯比赛时间 世界杯直播频道
- Cannon CP, et 世界杯直播频道 al. N Engl J Med. 2004;350:1495-1504.
- LaRosa JC, et al. N Engl J Med. 2005;352:1425-1435.
- Pederson TR, et al. JAMA. 2005;294:2437-2445.
- Search Collaborative Group. Lancet 2010;376:1658–69.
- Cannon CP, et al. N Engl J Med. 2015;372:2387-2397.
- Repatha® U.S. Prescribing Information. Amgen. 世界杯比赛时间
- World Health Organization. Cardiovascular diseases (CVDs) fact sheet.http://www.who.int/mediacentre/factsheets/fs317/en/.
2026世界杯直播赛程 世界杯直播频道 Accessed October 世界杯直播频道 30, 2017.
